Core Viewpoint - Company expects a significant decrease in net profit for 2025, projecting between RMB 40 million to 48 million, which represents a year-on-year decline of 62.23% to 68.52 due to industry pressures [1] Financial Performance - The anticipated decline in net profit is primarily attributed to the impact of centralized procurement in the in vitro diagnostic industry, leading to price pressures on the company's main products and a decrease in main business revenue [1] - The company reported a reduction in non-recurring gains such as government subsidies compared to the previous year [1] Strategic Initiatives - To enhance core competitiveness, the company maintains a high level of investment in product innovation [1] - The company adheres to a long-term operational philosophy of serving human health through leading technology and innovative products, leveraging its proprietary LiCA® technology platform [1] - The company is focused on a dual-driven strategy of import substitution and clinical interactive innovation to create high-cost performance clinical products [1] Future Outlook - The company plans to continue its innovation-driven development path, strengthen cost management, actively respond to industry changes, and steadily advance the construction of core competitiveness to achieve sustainable high-quality development [1]

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑;主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 智通财经APP讯，赛科希德(688338.SH)发布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%;实现归属于母公司所有者的净利润8714.3万元，同比下降22.88%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑；主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 格隆汇1月28日丨赛科希德(688338.SH)公布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%；实现归属于母公司所有者的净利润8714.32万元，同比下降22.88%；实现归属于 母公司所有者的扣除非经常性损益的净利润8141.81万元，同比下降26.31%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑；主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 格隆汇1月28日丨赛科希德(688338.SH)公布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%；实现归属于母公司所有者的净利润8714.32万元，同比下降22.88%；实现归属于 母公司所有者的扣除非经常性损益的净利润8141.81万元，同比下降26.31%。 ...

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field through research, production, and technical services [1] Group 2: Technological Advancements - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening and precise tracing capability [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other coexisting pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technological capabilities of Huajian Medical in public health emergencies and is a significant validation of its strategic direction [4] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" and enhancing the innovative efficiency and commercial value of enterprises within its ecosystem [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 華檢醫療控股有限公司 ETHK Labs Inc. （於開曼群島註冊成立之有限公司） （前稱 IVD Medical Holding Limited ） （股份代號：1931） 自願性公告 關於子公司成功研發尼帕病毒檢測雙平台解決方案及 集 團AI醫療戰略升級的進展 一、背景與契機 近 日，印 度 西 孟 加 拉 邦 暴 發 尼 帕 病 毒 疫 情，世 界 衛 生 組 織 已 將 其 列 為 致 命 性 人 畜 共 患 病 毒，感 染 死 亡 率 可 達40%至75%，且 目 前 尚 無 特 效 療 法 或 疫 苗。此 類 新 發 突 發 傳 染 病 疫 情 凸 顯 全 球 公 共 衛 生 體 系 對 快 速、精 準 診 斷 與 預 警 能 力 的 迫 切 需 求。 作 為 長 期 深 耕 生 命 科 學 領 域 的 高 科 技 知 識 產 權 資 ...

Core Viewpoint - The recent long-term procurement contract worth 600 million yuan between Mingji Hospital and Hefei China reflects both companies' operational anxieties, with Mingji Hospital needing to implement its expansion plans and Hefei China facing significant performance declines due to industry pressures [1][5][8]. Group 1: Company Performance - Hefei China is experiencing a significant downturn, with a projected revenue decline of 26.67% to 689 million yuan for 2025 and a shift from a net profit of 27.57 million yuan to a loss between 25 million and 36 million yuan [5][7]. - The company's losses are attributed to the implementation of centralized procurement policies in the in vitro diagnostics industry, which have drastically reduced procurement prices and squeezed sales revenue and gross margins [7][11]. - Despite cost control measures, Hefei China is unable to reduce fixed expenses proportionally to its declining revenue, leading to continued financial strain [7][11]. Group 2: Strategic Implications - The partnership between Mingji Hospital and Hefei China is driven by Mingji's urgent need for a stable supply chain to support its expansion plans following its recent IPO, where it raised approximately 555 million HKD [8][11]. - Mingji Hospital's operational model is limited by its higher pricing compared to public hospitals and a narrow customer base, which constrains its growth potential [11][15]. - The exclusive supply agreement with Hefei China may limit Mingji Hospital's ability to negotiate prices and manage costs effectively, especially in a context of increasing centralized procurement [11][12]. Group 3: Contractual Risks - The eight-year procurement agreement includes clauses for price adjustments based on market fluctuations, which could significantly impact Hefei China's profit margins and overall financial health [12][15]. - Payment terms require Hefei China to front nearly four months of payment for supplies, increasing its cash flow pressure amid ongoing losses [13][15]. - The lack of clear fallback provisions in the contract raises concerns about potential disputes and the overall stability of the partnership [12][14].

1月27日，热景生物涨5.05%，截至发稿，报154.89元/股，成交2.70亿元，换手率1.92%，总市值143.60 亿元。 资料显示，北京热景生物技术股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业基地庆 丰西路55号院7号楼1-5层，成立日期2005年6月23日，上市日期2019年9月30日，公司主营业务涉及研 发、生产和销售体外诊断试剂及仪器。主营业务收入构成为：检测试剂70.87%，检测仪器19.79%，其 他8.17%，生物原料1.17%。 截至发稿，农冰立累计任职时间7年222天，现任基金资产总规模126.84亿元，任职期间最佳基金回报 174.01%， 任职期间最差基金回报-1.57%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.c ...

Core Viewpoint - The stock of Capbio has experienced a consecutive two-day limit-up, indicating strong market interest, particularly due to recent Nipah virus infection cases in Eastern India, which aligns with the company's product offerings in virus detection [1] Group 1: Stock Performance - Capbio's stock reached a limit-up at 13:08 today, with a trading volume of 1.275 billion yuan and a turnover rate of 24.53% [1] Group 2: Product and Market Position - The company possesses Nipah virus nucleic acid test kits, which are relevant for epidemic monitoring and border control [1] - As a leading integrated supplier of molecular diagnostic products and services in China, Capbio has developed products for infectious disease testing, covering clinical diagnosis in hospitals and public health prevention [1] Group 3: Research and Development - Capbio is advancing clinical research on HPV infection treatment, with international product deployment across multiple countries and regions [1] - The diversification of the company's business may enhance market attention and support its operations [1] Group 4: Market Trends - The virus prevention concept sector is gaining market attention, and changes in related demand may provide support for the company's business [1]

Group 1 - The core viewpoint of the news is that Antu Biology's stock has increased by 5.98%, reaching a price of 39.54 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 22.594 billion yuan [1] - Antu Biology, established on September 15, 1999, and listed on September 1, 2016, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with its main business revenue composition being 86.63% from reagents, 10.99% from instruments, 1.40% from other sources, and 0.98% from maintenance income [1] - Changjiang Asset Management holds a significant position in Antu Biology through its fund, Changjiang Xuri Mixed A (021015), which held 71,000 shares in the fourth quarter, accounting for 2.47% of the fund's net value, ranking as the tenth largest holding [1] Group 2 - The fund manager of Changjiang Xuri Mixed A (021015) is Shi Zhan, who has been in the position for 4 years and 30 days, with the fund's total asset size being 802 million yuan [2] - During Shi Zhan's tenure, the best fund return was 53.53%, while the worst return was 48.76% [2]